|
| Reference | Design | Comparisons | Bloodletting regimen | Treatment frequency and duration | Outcomes |
|
| Gan 2018 [25] | Parallel, 2 arms | bloodletting, 30
cetirizine, 30 | disposable syringe needle with cupping;
Geshu (BL 17), Feishu (BL 13), Pishu (BL 20) | every other day; a total of 4 times | response rate;
recurrence rate;
adverse events |
|
| Shi 2016 [26] | Parallel, 2 arms | bloodletting, 33
cetirizine, 33 | triangle-edged needle with cupping;
Feishu (BL 13), Pishu (BL 20), Quchi (LI 11), Dazhui (DU 14), Xuehai (SP 10), Zusanli (ST 36) | every other day; duration not mentioned | response rate;
recurrence rate |
|
| Li and Yin 2015 [27] | Parallel, 2 arms | bloodletting, 27
cetirizine, 27 | triangle-edged needle with cupping;
Yuji (LU 10), Dazhui (DU 14), Weizhong (BL 40), Chize (LU 5) | every other day; a total of 4 weeks | response rate;
disease activity control;
recurrence rate;
adverse events |
|
| Li 2013 [28] | Parallel, 2 arms | bloodletting, 36
loratadine, 36 | triangle-edged needle with cupping;
Xuehai (SP 10), Quchi (LI 11), Weizhong (BL 40) | every 3 days; 3 times for a course, a total of 2 courses | response rate;
adverse events |
|
| Wu et al. 2010 [29] | Parallel, 2 arms | bloodletting, 30
cetirizine, 30 | plum-blossom needle with cupping;
Du meridian and Bladder Meridian | every other day; 10 times a course, a total of 2 courses, 5 days interval between courses | response rate |
|
Zhao 2013 [30]
unpublished thesis | Parallel, 3 arms | bloodletting, 30
mizolastine, 30
bloodletting plus mizolastine, 30 | triangle-edged needle with cupping;
Dazhui (DU 14), Feishu (BL 13), Geshu (BL 17), Ganshu (BL 18), Pishu (BL 20) | every other day; 4 weeks | response rate;
recurrence rate;
adverse events |
|
| Lv et al. 2006 [31] | Parallel, 2 arms | bloodletting plus cetirizine, 62
cetirizine, 48 | triangle-edged needle with cupping;
Dazhui (DU 14), Feishu (BL 13), Dachangshu (BL 25), Pishu (BL 20), Shenshu (BL 23) | once a days for consecutive 4 days as a course; 3 days interval between courses; a total of 4 weeks | response rate;
recurrence rate;
adverse events |
|
